Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 1.73M +45.7% |
| Revenue (ttm) | 21.13M -28.9% |
| Net Income | -2.19M |
| EPS | -1.15 |
| Shares Out | 14.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 515,732 |
| Average Volume | 729,309 |
| Open | 0.1170 |
| Previous Close | 0.1163 |
| Day's Range | 0.1160 - 0.1192 |
| 52-Week Range | 0.1075 - 2.8200 |
| Beta | 0.03 |
| RSI | 37.74 |
| Earnings Date | Mar 13, 2026 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
Lilly's $3.5B manufacturing facility in PA to produce next-gen GLP-1 that promises “even more weight loss”
Eli Lilly Chair & CEO Dave Ricks sits down with CNBC’s Annika Constantino to discuss the fourth location Lilly has committed to for “reshoring” pharmaceutical manufacturing in the U.S. The facility wi...
Corcept Therapeutics (CORT) Shares Drop After FDA Feedback
Corcept Therapeutics (CORT) Shares Drop After FDA Feedback
Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth
Regeneron REGN Q4 2025 earnings call recap: DUPIXENT, EYLEA HD and LIBTAYO growth, 2026 guidance, FDA approval outlook and pipeline catalysts—read now.
Analysts Maintain Bull Case On ResMed Despite Competition Concerns
On Thursday, ResMed Inc (NYSE: RMD) reported that second-quarter fiscal 2026 adjusted earnings of 2.81, beating the consensus of $2.72 . Quarterly sales increased 11% year over year to $1.42 billion,...
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
FDA approved Tenpoint's Yuvezzi eye drop for presbyopia, adding competition for LENZ's VIZZ as analysts say the recent stock drop may be overdone and see blockbuster potential ahead.
5 Stocks Primed for a Turnaround in 2026
Everyone loves a good comeback story, and that's especially true in markets where business cycles ebb and flow. Last year's winners frequently turn into this year's laggards, and we've already seen ex...
Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory
Regeneron Pharmaceuticals Inc . (NASDAQ: REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71 . The company reported ...
Corcept Therapeutics (CORT) Stock Falls After FDA Rejects Drug Application
Corcept Therapeutics (CORT) Stock Falls After FDA Rejects Drug Application
FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock?
The target action date for orforglipron is now April 10.
Ultragenyx (RARE) Seeks FDA Approval for Gene Therapy UX111
Ultragenyx (RARE) Seeks FDA Approval for Gene Therapy UX111
Global Drug Device Combination Products Market to Reach USD 379.17 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The global drug device combination products market is projected to reach USD 379.17 billion by 2030, from USD 243.02 billion in 2025, at a CAGR of 9...
Corcept down as FDA revises rejection letter for hormonal disorder therapy
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade)
Summit Therapeutics nears a 2026 FDA decision for ivonescimab with $710M cash and Akesobio catalysts. Find out why SMMT stock is upgraded to hold.
GRAIL Submits FDA Premarket Approval Application For The Galleri MCED Test
(RTTNews) - GRAIL Inc. (GRAL), a healthcare company, announced the submission of the final module of the Premarket Approval or PMA application to the U.S. Food and Drug Administration or FDA for its G...
As billionaires chase immortality, this startup cofounded by a Harvard genetics professor gets FDA approval for the first partial de-aging human trial
Life Biosciences will test its gene therapy designed to partially reset a cell’s age and potentially reverse vision loss in patients with glaucoma and NAION.
GRAIL (GRAL) Seeks FDA Approval for Galleri Multi-Cancer Test
GRAIL (GRAL) Seeks FDA Approval for Galleri Multi-Cancer Test
KORU Medical (KRMD) Gains FDA Clearance for FreedomEDGE Infusion System
KORU Medical (KRMD) Gains FDA Clearance for FreedomEDGE Infusion System
Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product
Fractyl Health Inc. (NASDAQ: GUTS) stock plunged on Thursday after the company hinted at a change in its U.S. regulatory strategy for Revita. Fractyl Health sotck hit its 52-week low with a session v...
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway
On Thursday, the U.S. Food & Drug Administration (FDA) accepted Summit Therapeutics Inc.’s (NASDAQ: SMMT) Biologics License Application (BLA) seeking approval for ivonescimab in combination with chem...
ART100 Becomes Inspira's First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center
RA'ANANA, Israel, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN , IINNW)) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-su...
Summit Therapeutics (SMMT) Advances with FDA Filing for Cancer Treatment
Summit Therapeutics (SMMT) Advances with FDA Filing for Cancer Treatment
Summit Therapeutics (SMMT) Gains After FDA Accepts Key Cancer Drug Application
Summit Therapeutics (SMMT) Gains After FDA Accepts Key Cancer Drug Application
Unicycive Therapeutics Announces FDA Acceptance For Resubmitted Oxylanthanum Carbonate NDA
(RTTNews) - Unicycive Therapeutics, Inc. (UNCY), Thursday announced the the U.S. Food and Drug Administration has accepted the resubmission of its New Drug Application for oxylanthanum carbonate or OL...
Summit spikes as lead asset undergoes FDA review
Summit Therapeutics (SMMT) stock jumps as the FDA accepts its marketing application for lead asset ivonescimab, a rival to Merck's (MRK) Keytruda. Read more here.
FDA Accepts Unicycive Therapeutics' NDA Resubmission for Oxylanthanum Carbonate
FDA Accepts Unicycive Therapeutics' NDA Resubmission for Oxylanthanum Carbonate